Indolinone Derivatives Targeting Cell Cycle Kinases
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current indolinones do not effectively address excessive or abnormal cell proliferation associated with specific cell cycle kinases, which are linked to various diseases such as cancer and autoimmune disorders.
Innovation Solution
Development of new indolinones with specific structural formulas that inhibit specific cell cycle kinases, including compounds of general formula (1) where R1, R2, R3, and X are defined, which act as inhibitors of cyclin/CDK complexes, thereby controlling excessive cell proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional indolinones are used, then synthesis is relatively simple, but they do not effectively inhibit specific cell cycle kinases
Solution Approach 1:
The patent applies local quality by introducing specific functional groups (aminosulphonyl, alkoxy, hydroxyl) at particular positions (5-position) of the indolinone molecule to achieve selective kinase inhibition. This localized modification of molecular properties enables the compound to target specific cell cycle kinases while maintaining the core indolinone structure.
Solution Approach 2:
The patent employs parameter changes by systematically varying substituent groups (R1, R2, R3, X) at different positions of the indolinone molecule to optimize kinase inhibition activity. By changing chemical parameters such as substituent types and their positions, the compound achieves enhanced efficacy against specific cell cycle kinases.
2Reliability
If new indolinones with specific substituents are synthesized, then cell proliferation inhibition is improved, but synthesis complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the synthesis process into distinct steps: first forming the core indolinone structure, then introducing specific substituent groups at defined positions. This modular approach allows for systematic variation of R1, R2, R3, and X groups while maintaining a clear synthetic pathway, making the increased complexity manageable through structured synthesis.
Data Source
AI summary
The present invention encompasses compounds of general formula (1) wherein R1, R2, R3 and X are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.